Close
  • Latest News
  • Big Data and Analytics
  • Cloud
  • Networking
  • Cybersecurity
  • Applications
  • IT Management
  • Storage
  • Sponsored
  • Mobile
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
Read Down
Sign in
Close
Welcome!Log into your account
Forgot your password?
Read Down
Password recovery
Recover your password
Close
Search
Logo
Logo
  • Latest News
  • Big Data and Analytics
  • Cloud
  • Networking
  • Cybersecurity
  • Applications
  • IT Management
  • Storage
  • Sponsored
  • Mobile
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
More
    Home Applications
    • Applications
    • Database

    Judge Still Weighing PeopleSofts Poison Pill

    By
    Renee Boucher Ferguson
    -
    November 29, 2004
    Share
    Facebook
    Twitter
    Linkedin

      Delaware Chancery Court Judge Leo Strine is taking a second look at PeopleSofts poison pill and CAP (Customer Assurance Program) anti-takeover mechanisms.

      The judge, who in October heard Oracle Corp.s suit against PeopleSoft Inc. that seeks an injunction to block the pill and CAP, has scheduled additional hearings next month.

      The requested hearings, planned for Dec. 13 and 14, will give PeopleSoft attorneys a chance to provide more information on the companys rationale for rejecting Oracles $24-per-share bid, according to PeopleSoft spokesman Steve Swasey, in Pleasanton, Calif.

      Oracle and PeopleSoft have been locked in a fierce battle for control of PeopleSoft. Oracle launched its initial hostile takeover bid for the company in the summer of 2003 and has lowered and raised its bid nearly half a dozen times since.

      Earlier this month, the company made its “best and final” offer of $24 a share, and more than 60 percent of PeopleSofts shareholders agreed to tender their shares at that price.

      PeopleSofts board of directors, however, has steadfastly declined Oracles offers on the grounds that the offer undervalues the companys worth.

      In spite of the majority of shareholders who agreed to tender their shares, Oracle cannot acquire PeopleSoft without the poison pill stipulation being removed from the companys bylaws—a decision that is being weighed by Judge Strine.

      A poison pill measure—which is written into many companies bylaws—is triggered in the event of a hostile takeover, and in this case would flood the market with millions of PeopleSoft shares, making the transaction prohibitively expensive for Oracle.

      The Customer Assurance Program is unique to PeopleSoft. It also is triggered by a hostile takeover—and diminished support of the companys software—and looks to refund some PeopleSoft customers between two time to five times their license fees.

      The tit-for-tat wrangling between Oracle and PeopleSoft has already delayed Strines decision, which was expected sometime this month. In the meantime, Oracle has launched a proxy battle for PeopleSofts board.

      Last week, the company announced its slate of nominees for the four open seats on PeopleSofts board. The election will be held during PeopleSofts annual shareholder meeting in spring 2005. The date for that meeting has not yet been set.

      /zimages/1/28571.gifRead more here about Oracle putting forth a slate for PeopleSofts board.

      Should it prove successful in overtaking PeopleSofts board, Oracle will have the ability to nullify the poison pill and the customer assurance measures—with or without a nod of approval from the Delaware Chancery Court.

      /zimages/1/28571.gifCheck out eWEEK.coms for the latest news, reviews and analysis about productivity and business solutions.

      Renee Boucher Ferguson

      MOST POPULAR ARTICLES

      Big Data and Analytics

      Alteryx’s Suresh Vittal on the Democratization of...

      James Maguire - May 31, 2022 0
      I spoke with Suresh Vittal, Chief Product Officer at Alteryx, about the industry mega-shift toward making data analytics tools accessible to a company’s complete...
      Read more
      Cybersecurity

      Visa’s Michael Jabbara on Cybersecurity and Digital...

      James Maguire - May 17, 2022 0
      I spoke with Michael Jabbara, VP and Global Head of Fraud Services at Visa, about the cybersecurity technology used to ensure the safe transfer...
      Read more
      Cloud

      IGEL CEO Jed Ayres on Edge and...

      James Maguire - June 14, 2022 0
      I spoke with Jed Ayres, CEO of IGEL, about the endpoint sector, and an open source OS for the cloud; we also spoke about...
      Read more
      Applications

      Cisco’s Thimaya Subaiya on Customer Experience in...

      James Maguire - May 10, 2022 0
      I spoke with Thimaya Subaiya, SVP and GM of Global Customer Experience at Cisco, about the factors that create good customer experience – and...
      Read more
      Big Data and Analytics

      GoodData CEO Roman Stanek on Business Intelligence...

      James Maguire - May 4, 2022 0
      I spoke with Roman Stanek, CEO of GoodData, about business intelligence, data as a service, and the frustration that many executives have with data...
      Read more
      Logo

      eWeek has the latest technology news and analysis, buying guides, and product reviews for IT professionals and technology buyers. The site’s focus is on innovative solutions and covering in-depth technical content. eWeek stays on the cutting edge of technology news and IT trends through interviews and expert analysis. Gain insight from top innovators and thought leaders in the fields of IT, business, enterprise software, startups, and more.

      Facebook
      Linkedin
      RSS
      Twitter
      Youtube

      Advertisers

      Advertise with TechnologyAdvice on eWeek and our other IT-focused platforms.

      Advertise with Us

      Menu

      • About eWeek
      • Subscribe to our Newsletter
      • Latest News

      Our Brands

      • Privacy Policy
      • Terms
      • About
      • Contact
      • Advertise
      • Sitemap
      • California – Do Not Sell My Information

      Property of TechnologyAdvice.
      © 2022 TechnologyAdvice. All Rights Reserved

      Advertiser Disclosure: Some of the products that appear on this site are from companies from which TechnologyAdvice receives compensation. This compensation may impact how and where products appear on this site including, for example, the order in which they appear. TechnologyAdvice does not include all companies or all types of products available in the marketplace.

      ×